financetom
Business
financetom
/
Business
/
Pirelli considers US investment to curb tariffs impact
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pirelli considers US investment to curb tariffs impact
Feb 26, 2025 11:09 AM

MILAN, Feb 26 (Reuters) - Tyremaker Pirelli

will seek to limit the impact of possible tariffs, including by

expanding U.S. output, it said on Wednesday, while forecasting

an adjusted earnings before interest and tax (EBIT) margin of

around 16% for 2025, higher than last year.

The Italian tyremaker makes around 25% of its revenues on

the North American market.

"We are considering significant investments in the U.S. to

increase production capacity," Executive Vice-chairman Marco

Tronchetti Provera said in post-earnings call with analysts.

Pirelli is vulnerable to possible U.S. import tariffs, as it

mostly serves its North American market through tyre output from

its plants in Mexico, South America and Europe, even though it

has a plant in the U.S. state of Georgia.

Pirelli said its mitigation plan in the event of U.S.

tariffs also included a review of commercial policy based on

inflation expectations, CEO Andrea Casaluci told the same

analysts call.

Pirelli on Wednesday announced adjusted EBIT for the final

quarter of 2024 of 244.6 million euros ($257.10 million), up

11.5% year-on-year, and exceeding a 228 million euro analyst

consensus provided by the company.

It also posted a 15.7% adjusted EBIT margin for the whole of

2024, compared with a 15.5% target guided last August.

($1 = 0.9514 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Willis Towers Watson Strikes Co-Brokerage Agreement With The J. Morey Company
Willis Towers Watson Strikes Co-Brokerage Agreement With The J. Morey Company
Oct 2, 2024
01:55 PM EDT, 10/02/2024 (MT Newswires) -- Willis Towers Watson ( WTW ) said Wednesday it has struck a co-brokerage arrangement with The J. Morey Company, an Ori-gen family company. The agreement will align resources to deliver brokerage support and insurance solutions to North American exposures of companies with headquarters in Japan, the company said. Price: 296.76, Change: -3.82, Percent...
Nikola's hydrogen-powered truck deliveries to dealers rise 22% in Q3
Nikola's hydrogen-powered truck deliveries to dealers rise 22% in Q3
Oct 2, 2024
(Reuters) - Nikola ( NKLA ) said on Wednesday it delivered 88 hydrogen fuel cell electric trucks to its dealers in the third quarter, up from 72 trucks in the previous three-month period, signaling steady demand for the company's big rigs. The company had expected to sell between 80 and 100 units during the period. Nikola ( NKLA ) had...
Humana Faces Sharp Decline In Medicare Star Ratings For 2025, Braces For 2026 Revenue Hit
Humana Faces Sharp Decline In Medicare Star Ratings For 2025, Braces For 2026 Revenue Hit
Oct 2, 2024
According to preliminary data from the Centers for Medicare and Medicaid Services (CMS), Humana Inc. ( HUM ) faces a substantial drop in its Medicare Advantage (MA) Star Ratings for 2025. The data available in the CMS Plan Finder as of October 1, 2024, reveals that only 25% of Humana’s members are enrolled in plans rated four stars and above,...
Gilead Sciences Signs Licensing Deals With 6 Drugmakers to Manufacture HIV Prevention Drug Lenacapavir
Gilead Sciences Signs Licensing Deals With 6 Drugmakers to Manufacture HIV Prevention Drug Lenacapavir
Oct 2, 2024
09:11 AM EDT, 10/02/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Wednesday that it has signed non-exclusive, royalty-free voluntary licensing deals with six pharmaceutical companies to manufacture and sell generic lenacapavir for the prevention of HIV in 120 mostly low-income countries. The pharmaceutical companies include Dr. Reddy's Laboratories (RDY), Emcure, Eva Pharma, Ferozsons Laboratories, Hetero Drugs, and Viatris...
Copyright 2023-2025 - www.financetom.com All Rights Reserved